Lantern Pharma Inc. (LTRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LTRN Stock Price Chart Interactive Chart >
LTRN Price/Volume Stats
| Current price | $5.24 | 52-week high | $11.39 |
| Prev. close | $4.90 | 52-week low | $4.56 |
| Day low | $5.04 | Volume | 30,591 |
| Day high | $5.39 | Avg. volume | 36,482 |
| 50-day MA | $5.30 | Dividend yield | N/A |
| 200-day MA | $6.04 | Market Cap | 56.75M |
Lantern Pharma Inc. (LTRN) Company Bio
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Latest LTRN News From Around the Web
Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual MeetingDALLAS, September 23, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at the Society of Hematologic |
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.DALLAS, September 19, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potenti |
Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer CandidateLantern Pharma Inc (NASDAQ: LTRN) will present preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research Special Conference. LP-184 is a small molecule drug candidate and next-generation acylfulvene that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair (DDR) genes and overexpressing the enzyme PTGR1. Pancreatic cancer cells are expected to be sensitive to LP-184 treatment, as arou |
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic CancerDALLAS, September 14, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Confer |
Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022DALLAS, August 30, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company’s CEO & President, Panna Sharma, will be speaking at H.C. Wainwright’s 24th Annual Global Investment Conference, which is being held September 12-14, 2022 in New York, NY. |
LTRN Price Returns
| 1-mo | 4.80% |
| 3-mo | -9.50% |
| 6-mo | -25.25% |
| 1-year | -44.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -34.34% |
| 2021 | -58.55% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...